drugset / Trial / NCT00195598

Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder

NCT00195598

Phase 3 Completed 70 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this pilot study is to evaluate the improvement in social function following therapy with venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine. An additional purpose of this pilot study is to obtain the tolerability of using venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine.

Timeline

Start
2005-01
Primary completion
2006-04
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Paroxetine Small molecule
Subject Venlafaxine Small molecule

Indications